Contributed by  

Francis Medical Inc.

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer (VAPOR 2)

Overview

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device (“Vanquish”) in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.

Official Title

Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for Prostate Cancer

Conditions 

Prostate Cancer

ClinicalTrials.gov ID

NCT05683691

Interested In Learning More?

Visit the clinicaltrials.gov to read the full Clinical Trial

Back to

All Clinical Trials

Stay UPDATED

More Resources

Search Directory

Talk to a physician today to learn more about a treatment that’s right for you.

FAQs

Learn more about focal therapy by reading commonly asked questions.

Publications

Learn more about new diagnostic and treatment strategies.

Proudly Sponsored By